At ASCO 2024, Avan J. Armaghani, MD, highlights two key presentations. First, a retrospective study on adjuvant endocrine therapy in ER-low breast cancer (1%-10% ER-positivity) demonstrated that patients who skipped this therapy had significantly worse overall survival, especially those who received neoadjuvant chemotherapy without a complete response. Second, an update on the NATALEE study showed that adjuvant ribociclib improved invasive disease–free and distant recurrence–free survival in patients with node-negative breast cancer.
These findings suggest promising treatment options while raising important questions about which subgroups would benefit most. Dr Armaghani notes that the discussions and questions sparked by these studies are expected to continue and evolve.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2024: Two Key Insights on New Early Breast Cancer Data - Medscape - Jun 07, 2024.
Comments